Seroatlas · Human Serome Atlas

SSX5

Protein SSX5

Also known as: SSX5_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O60225
Gene: SSX5
Ensembl: ENSG00000165583
Chromosome: X
Canonical length: 188 aa
Protein class: Predicted intracellular proteins
Subcellular location: Nucleoplasm,Nucleoli

OverviewNCBI Gene

The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. While some of the related SSX genes are involved in t(X;18)(p11.2;q11.2) translocations that are characteristically found in all synovial sarcomas, this gene does not appear to be involved in such translocations. Two transcript variants encoding distinct isoforms have been identified for this gene. [provided by RefSeq, Jul 2013]

Canonical amino-acid sequenceUniProt

188 residues, UniProt reviewed canonical sequence.

>O60225|SSX5
     1  MNGDDAFVRR PRVGSQIPEK MQKAFDDIAK YFSEKEWEKM KASEKIIYVY MKRKYEAMTK
    61  LGFKATLPPF MRNKRVADFQ GNDFDNDPNR GNQVEHPQMT FGRLQGIFPK ITPEKPAEEG
   121  NDSKGVPEAS GPQNNGKQLR PSGKLNTSEK VNKTSGPKRG KHAWTHRVRE RKQLVIYEEI
   181  SDPQEDDE

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SSX5 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.61
Highest tissue expression: 0.6 nTPM

Expression across tissuesHPA

Tissue

testis: 0.6 nTPM
bone marrow: 0.2 nTPM
heart muscle: 0.2 nTPM
spleen: 0.2 nTPM
fallopian tube: 0.1 nTPM
parathyroid gland: 0.1 nTPM

Single-cell type

early primary spermatocytes: 5.2 nCPM
differentiating spermatogonia: 4.3 nCPM
mast cells: 1.1 nCPM
undifferentiated spermatogonia: 1.1 nCPM
early spermatids: 0.4 nCPM
lymphatic endothelial cells: 0.4 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

thalamus: 4 nTPM
amygdala: 3.9 nTPM
cerebral cortex: 3.9 nTPM
pons: 3.9 nTPM
hypothalamus: 3.7 nTPM
medulla oblongata: 3.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about SSX5.

Disease | ImmuneIEDB

Conditions an epitope on SSX5 was assayed in.

hepatocellular carcinoma T cell
melanoma T cell

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.85
gnomAD pLI: 0
gnomAD missense Z: -1.31
DepMap mean gene effect: -0.33
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

regulation of DNA-templated transcription

Cellular components

nucleus

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SSX5 as an antibody target. Whether an autoantibody or antibody against SSX5 could matter depends on whether native SSX5 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SSX5 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Source-annotated serology context

The source annotations explicitly mention antibody, autoantibody, autoantigen, or autoimmune context. This is biological context, not study-specific reactivity.

They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy.

Loading the interactive Seroatlas protein explorer...